dc.contributor.author | Szejniuk, Weronika Maria | |
dc.contributor.author | Nielsen, Martin Skovmos | |
dc.contributor.author | Brønnum, Dorthe | |
dc.contributor.author | Takacs-Szabo, Z | |
dc.contributor.author | Weinreich, Ulla Møller | |
dc.contributor.author | Pilegaard Thomsen, L | |
dc.contributor.author | Bøgsted, Martin | |
dc.contributor.author | Jensen, Ingelise | |
dc.contributor.author | McCulloch, Tine | |
dc.contributor.author | Falkmer, Ursula | |
dc.contributor.author | Carl, Jesper | |
dc.contributor.author | Røe, Oluf Dimitri | |
dc.date.accessioned | 2022-05-02T13:10:48Z | |
dc.date.available | 2022-05-02T13:10:48Z | |
dc.date.created | 2020-02-18T17:18:57Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Clinical and Translational Radiation Oncology. 2019, 19 103-109. | en_US |
dc.identifier.issn | 2405-6308 | |
dc.identifier.uri | https://hdl.handle.net/11250/2993675 | |
dc.description.abstract | Introduction
The aim of the study was to investigate repetitive fractional exhaled nitric oxide (FeNO) measurements during high-dose radiation therapy (HDRT) and to evaluate the use of FeNO to predict symptomatic radiation pneumonitis (RP) in patients being treated for non-small cell lung cancer (NSCLC).
Materials and methods
A total of 50 patients with NSCLC referred for HDRT were enrolled. FeNO was measured at baseline, weekly during HDRT, one month- and every third month after HDRT for a one-year follow-up period. The mean FeNO(visit 0-6) was calculated using the arithmetic mean of the baseline and weekly measurements during HDRT. Patients with grade ≥ 2 of RP according to the Common Terminology Criteria for Adverse Events (CTCAE) were considered symptomatic.
Results
A total of 42 patients completed HDRT and weekly FeNO measurements. Grade ≥ 2 of RP was diagnosed in 24 (57%) patients. The mean FeNO(visit 0-6) ± standard deviation in patients with and without RP was 15.0 ± 7.1 ppb (95%CI: 12.0–18.0) and 10.3 ± 3.4 ppb (95%CI: 8.6–11.9) respectively with significant differences between the groups (p = 0.0169, 95%CI: 2.3–2.6). The leave-one-out cross-validated cut-off value of the mean FeNO(visit 0-6) ≥ 14.8 ppb was predictive of grade ≥ 2 RP with a specificity of 71% and a positive predictive value of 78%.
Conclusions
The mean FeNO(visit 0-6) in patients with symptomatic RP after HDRT for NSCLC was significantly higher than in patients without RP and may serve as a potential biomarker for RP. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: A pilot study | en_US |
dc.title.alternative | Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: A pilot study | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 103-109 | en_US |
dc.source.volume | 19 | en_US |
dc.source.journal | Clinical and Translational Radiation Oncology | en_US |
dc.identifier.doi | 10.1016/j.ctro.2019.09.004 | |
dc.identifier.cristin | 1795585 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |